Annovis Bio Inc ANVS 深 沪
等待开盘 05-21 09:30:00 美东时间
2.04
+0.100
+5.15%
华盛通- 最 高2.04
- 今 开1.80
- 成交量 394.32万股
- 最 低 1.75
- 昨 收 1.94
- 总市值 7067.96万
- 52周最高 5.50
- 市盈率 静 --
- 换手率 11.38%
- 52周最低 1.5407
- 委 比 -44.18%
- 总股本 3464.69万
- 历史最高 132.00
- 量 比 4.65
- 振 幅 14.95%
- 历史最低 1.11
- 每 手 1
- 风险率 0.67%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why 8x8 Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expected Q4 results, with adjusted earnings of 11 cents per share and revenue of $185.25 million. GCL, PETZ, WOK, MEHA, HAO, TDIC, FEED, KELYA, and AMC were among the top gainers, while RUBI, AMIX, IPW, ANVS, and WGRX were among the top losers in pre-market trading.
05-20 16:31
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Co-Diagnostics (NASDAQ:CODX) shares rose 20.8% to $2.38 during Tuesday...
05-20 05:06
Annovis Bio shares are trading lower after the company announced a $250 million public offering.
Annovis Bio shares are trading lower after the company announced a $250 million...
05-20 04:24
Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst consensus estimate of $(0.40) by 61.54 percent. This is a 96.88 percent decrease over losses of $(0.32) per share from the
05-15 19:38
Annovis Bio Q1 FY26 net loss widens to $17.61 million
Annovis Bio Q1 FY26 net loss widens to $17.61 million Annovis Bio posted a net loss of USD 17.61 million, or USD 0.63 per share, for first-quarter 2026, widening from a net loss of USD 5.54 million, or USD 0.32 per share, a year earlier. Research and development expense more than doubled to USD 16.
05-15 19:32
Annovis Bio Announces New Publication Titled Buntanetap Treatment In Mild To Moderate Alzheimer's Disease: Phase 2/3 Study In Peer-Reviewed Journal Nature NPJ Dementia
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic proteins as well as biomarkers of neuroinflammation and neurodegenerationBuntanetap was safe and well-tolerated, including in
04-28 20:10
Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.
Annovis Bio shares are trading lower after the company announced pricing of its...
04-09 22:31
Annovis Bio Issued New U.S. Patent For Prevention And Treatment Of Neurological Injuries From Brain Infections
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's
04-02 19:31
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries
Annovis Bio wins U.S. patent for buntanetap to treat brain infection-related injuries Annovis Bio secured U.S. Patent No. 12,582,632 B2 covering use of buntanetap to prevent or treat neurological injuries linked to brain infections. Patent claims include preventive use in at-risk healthy individuals
04-02 19:30
